Treatment Strategy & Standard of Care for wAIHA

The goal of treating warm Autoimmune Hemolytic Anemia (wAIHA) is to stop the immune system from destroying your red blood cells and to restore your blood counts to a safe level ^[1]. Modern treatment follows a standardized “ladder” approach, moving from well-established therapies to more targeted options if the initial response isn’t enough ^[2][3].

Supportive Care & Emergency Stabilization

In addition to targeted therapies, many patients require immediate supportive care:

• Folic Acid (Folate): Because your bone marrow is working in overdrive to replace destroyed red blood cells, doctors routinely prescribe a daily folic acid supplement to prevent a secondary deficiency ^[4].
• Blood Transfusions: Severe wAIHA often presents as an acute crisis requiring emergency blood transfusions ^[5]. Note: Because your blood contains autoantibodies, cross-matching donor blood takes significantly longer than normal. Expect delays in receiving blood; this is a common part of the process and hospitals have protocols for it ^[5].

First-Line: The “Reset Button”

The standard first treatment for almost everyone diagnosed with wAIHA is corticosteroids (such as prednisone) ^[2][5].

• How they work: Steroids act as a powerful “reset button” for your immune system, quickly dampening the attack on your red blood cells ^[5].
• Immediate Side Effects: In the first few weeks, you may experience short-term side effects like insomnia, severe mood swings, feeling jittery, a ravenous appetite, and temporary facial swelling (often called “moon face”) ^[6]. These are normal and usually temporary as the dose is lowered.
• What to expect: Most patients see an improvement in their blood counts within 1 to 3 weeks ^[2].
• The Taper: Steroids cannot be stopped suddenly. Once your blood counts are stable, your doctor will slowly lower (taper) the dose over several months to prevent the disease from “flaring” back up ^[2].

Second-Line: Rituximab

If steroids don’t work, or if the anemia returns as the dose is lowered, doctors move to second-line therapy. Rituximab is now the preferred choice for most patients ^[7][8].

• How it works: Rituximab is a monoclonal antibody that specifically targets and removes the B-cells in your immune system that are producing the harmful antibodies ^[7].
• Infection Risks: Because Rituximab destroys B-cells, it severely blunts your body’s ability to respond to vaccines for months and carries significant infection risks, including Hepatitis B reactivation ^[7]. You must discuss and receive any necessary vaccinations before starting this therapy.
• Why it’s preferred: In the past, surgery to remove the spleen was the main second-line treatment. Rituximab is highly effective and avoids the risks of major surgery and the lifelong infection risks of losing your spleen ^[7][9].

The Role of Splenectomy

A splenectomy (surgical removal of the spleen) remains a reliable option but is generally used only if Rituximab fails or isn’t an option ^[5][10]. Since the spleen is the primary place where the “tagged” red blood cells are destroyed, removing it can stop the hemolysis ^[4]. However, it is a permanent change that requires specific vaccinations beforehand to protect against certain bacteria ^[9].

Emerging and Refractory Options

For cases that are refractory (meaning they don’t respond to standard treatments), researchers are developing new, highly targeted therapies:

• SYK Inhibitors (e.g., Fostamatinib): These block the signal that tells immune cells to “eat” the red blood cells ^[11].
• FcRn Inhibitors (e.g., Nipocalimab): These help the body clear out the harmful IgG antibodies much faster than normal ^[12].
• Complement Inhibitors (e.g., Eculizumab): Sometimes used in life-threatening emergencies, especially if the C3d marker was found in your lab work ^[13].

Treatment Decision Tree